Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD
Recruiting
Phase 2
Interventional Study
Chronic Granulomatous Disease X-linked (X-CGD)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 45
- Sex
- Male
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 3 (estimated)
- Sponsor
- IRCCS San Raffaele · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a phase II exploratory study conducted to evaluate the safety and efficacy of the combination of Ibuprofen, G-CSF and Plerixafor as stem cell mobilization regimen in patients affected by X-CGD.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Genetic diagnosis of X-CGD
* 18-45 years of age
* Karnofsky Index \> 80 %
* Adequate cardiac, renal, hepatic and pulmonary function.
* Negative thrombophilic screen and negative history for previous thrombotic events
* Written informed consent
Exclusion Criteria:
* Previous …
Contacts